Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
SALT LAKE CITY—Harrison Robert Gardner, Chief Information Officer at Sera Prognostics , Inc. (NASDAQ:SERA), recently sold a portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Gardner disposed of 3,610 shares of Class A Common Stock on February 13, 2025. The shares were sold at a weighted average price of $4.28, yielding a total transaction value of approximately $15,450. The transaction comes as SERA trades near its 52-week low of $3.84, with the stock down about 48% year-to-date according to InvestingPro data.
This transaction was executed as part of a pre-established Rule 10b5-1 trading plan, which Gardner adopted on May 14, 2024. Following this sale, Gardner retains ownership of 103,112 shares in the company. The sale involved multiple transactions with prices ranging from $4.20 to $4.36 per share. InvestingPro analysis reveals the company maintains a healthy balance sheet with more cash than debt and a current ratio of 2.11. Subscribers can access 8 additional key insights and a comprehensive Pro Research Report, part of InvestingPro's coverage of over 1,400 US stocks.
In other recent news, Sera Prognostics, a medical laboratory services provider, has halted its $50 million stock offering, as per a recent SEC filing. The company had previously intended to sell up to $50 million of its Class A common stock through TD Securities (USA) LLC, but no shares were sold under this arrangement. Despite this, Sera Prognostics has reserved the right to initiate a new offering after filing a new prospectus or prospectus supplement.
In another development, Sera Prognostics has initiated a public offering of its Class A common stock and pre-funded warrants. The proceeds from this offering are aimed at expanding U.S. commercial operations, preparing for growth in the EU, seeking FDA approval for its PreTRM test, and other corporate purposes. The offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets.
Additionally, the Society for Maternal Fetal Medicine (SMFM) has published an abstract with topline results from the PRIME study, a project of Sera Prognostics. The study's findings, focusing on improving neonatal outcomes through prematurity risk assessment combined with clinical interventions, are set to be presented in detail later this month. Following the presentation, Sera Prognostics plans to host a conference call and live audio webcast for a more in-depth discussion of the PRIME study's outcomes. These are the recent developments concerning Sera Prognostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.